A Study of Lebrikizumab in Adolescent Participants With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and a Second Controller Medication

Inclusion Criteria:

- Asthma diagnosis for greater than or equal to (>/=) 12 months prior to Visit 1

- Bronchodilator response during screening

- Pre-bronchodilator FEV1 of 40 percent (%) - 90% predicted at both Visits 2 and 3

- On high dose ICS therapy for >/= 6 months prior to Visit 1

- On an eligible second controller medication for 6 months prior to Visit 1

- Uncontrolled asthma as defined by the protocol both during screening and at the time
of randomization

- Demonstrated adherence with controller medication during the screening period

Exclusion Criteria:

- History of severe allergic reaction or anaphylactic reaction to a biologic agent or
known hypersensitivity to any component of the lebrikizumab injection

- Maintenance oral corticosteroid therapy within 3 months prior to Visit 1

- Treatment with systemic (oral, intravenous [IV], or intramuscular [IM])
corticosteroids within 4 weeks prior to Visit 1 or during the screening period

- Treatment with intra-articular corticosteroids within 4 weeks prior to Visit 1 or
during the screening period or anticipated need for intra-articular corticosteroids
during the course of the study

- Infection that meets the following criteria: Any infection requiring hospital
admission or requiring treatment with IV or IM antibiotics within 4 weeks prior to
Visit 1 or during screening; any active infection that required treatment with oral
antibiotics within 2 weeks prior to Visit 1 or during screening; upper or lower
respiratory tract infection within 4 weeks prior to Visit 1 or during screening;
active parasitic infection or Listeria monocytogenes infection within 6 months prior
to Visit 1 or during screening

- History of active tuberculosis requiring treatment

- Known immunodeficiency, including, but not limited to, human immunodeficiency virus
(HIV) infection

- Evidence of acute or chronic hepatitis or known liver cirrhosis

- History of cystic fibrosis, bronchiectasis, and/or other clinically significant lung
disease other than asthma

- Diagnosis or history of malignancy or current evaluation for potential malignancy

- Current smoker or former smoker with a history of greater than (>) 10 pack-years

- History of alcohol or drug abuse

- Past and/or current use of any anti- interleukin (IL) -13 or anti-IL-4/IL-13 therapy,
including lebrikizumab

- Use of other monoclonal antibody therapy, including omalizumab, within 6 months or 5
drug half-lives (whichever is longer) prior to Visit 1

- Initiation of or change in allergen immunotherapy within 3 months prior to Visit 1 or
during screening

- History of bronchial thermoplasty